K-232 clinical pharmacology study
Phase 3
Completed
- Conditions
- healthy males
- Registration Number
- JPRN-jRCT2080225220
- Lead Sponsor
- Kowa Company, Ltd.
- Brief Summary
Pharmacokinetic analyses demonstrated rapid elimination of unchanged ripasudil, ripasudil metabolite M1, and unchanged brimonidine from the plasma following topical instillation K-232. K-232 provided significantly greater reductions in IOP with 8 days of short-term instillation and similar safety profile compared with each agent as monotherapy in healthy adult volunteers.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- completed
- Sex
- Male
- Target Recruitment
- 50
Inclusion Criteria
healthy males
Exclusion Criteria
1.Subjects who having a history of drug allergy
2.Subjects thought to wear contact lenses during this trial
etc.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method